Cooper Companies (NASDAQ:COO) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Cooper Companies (NASDAQ:COO) from a hold rating to a buy rating in a report released on Friday morning.

COO has been the subject of a number of other research reports. Morgan Stanley boosted their price objective on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a research report on Tuesday, September 10th. Stifel Nicolaus reissued a “buy” rating and set a $115.00 price target (up from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Jefferies Financial Group upgraded Cooper Companies from a “hold” rating to a “buy” rating and upped their price target for the stock from $107.00 to $115.00 in a research note on Tuesday, July 16th. Wells Fargo & Company boosted their price objective on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Finally, Robert W. Baird upped their target price on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $117.00.

Cooper Companies Stock Performance

COO stock traded up $0.42 on Friday, hitting $103.75. The company’s stock had a trading volume of 679,183 shares, compared to its average volume of 1,167,679. The firm has a 50 day moving average of $107.30 and a two-hundred day moving average of $97.54. Cooper Companies has a 1 year low of $80.48 and a 1 year high of $112.38. The stock has a market cap of $20.66 billion, a price-to-earnings ratio of 57.80, a price-to-earnings-growth ratio of 2.24 and a beta of 0.99. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. During the same period in the prior year, the company posted $0.84 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities analysts predict that Cooper Companies will post 3.65 EPS for the current fiscal year.

Insider Buying and Selling at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total value of $12,710,065.76. Following the transaction, the chief executive officer now directly owns 165,273 shares in the company, valued at $18,267,624.69. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Brian G. Andrews sold 24,788 shares of Cooper Companies stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the sale, the chief financial officer now owns 6,614 shares in the company, valued at approximately $700,422.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Albert G. White III sold 114,992 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cooper Companies

A number of institutional investors have recently bought and sold shares of COO. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Cooper Companies during the first quarter valued at approximately $1,433,000. Nordea Investment Management AB lifted its holdings in Cooper Companies by 315.1% in the first quarter. Nordea Investment Management AB now owns 16,120 shares of the medical device company’s stock valued at $1,642,000 after acquiring an additional 12,237 shares during the period. Quent Capital LLC increased its position in shares of Cooper Companies by 300.0% in the first quarter. Quent Capital LLC now owns 828 shares of the medical device company’s stock valued at $84,000 after buying an additional 621 shares in the last quarter. Texas Permanent School Fund Corp raised its position in Cooper Companies by 301.8% during the first quarter. Texas Permanent School Fund Corp now owns 41,086 shares of the medical device company’s stock worth $4,169,000 after acquiring an additional 30,860 shares during the period. Finally, Duality Advisers LP raised its position in shares of Cooper Companies by 39.8% in the first quarter. Duality Advisers LP now owns 5,890 shares of the medical device company’s stock valued at $598,000 after buying an additional 1,677 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.